Aadi Bioscience, Inc. (AADI)

Market Cap	54.72M
Revenue (ttm)	25.07M
Net Income (ttm)	-61.69M
Shares Out	24.65M
EPS (ttm)	-2.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,649
Open	2.200
Previous Close	2.210
Day's Range	2.200 - 2.280
52-Week Range	1.210 - 5.700
Beta	0.37
Analysts	Hold
Price Target	1.75 (-21.17%)
Earnings Date	Nov 6, 2024

About AADI

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: AADI
• Website: https://aadibio.com

Financial Performance

In 2023, Aadi Bioscience's revenue was $24.35 million, an increase of 60.06% compared to the previous year's $15.22 million. Losses were -$65.77 million, 8.68% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AADI stock is "Hold." The 12-month stock price forecast is $1.75, which is a decrease of -21.17% from the latest price.

Price Target

$1.75

(-21.17% downside)

Analyst Consensus: Hold